1. Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register
- Author
-
Rossella, Marcucci, Poli, Daniela, SOD Malattie Aterotrombotiche, Azienda Ospedaliero Universitaria-Careggi, Walter Ageno, Firenze., Giovanna, Colombo, UOSD Degenza Breve, e Internistica, Centro trombosi Ospedale di Circolo, Chiara Ambaglio, Varese., UOSD SIMT Servizio di Immunoematologia, e Medicina Trasfusionale, Ospedale di Treviglio, – Caravaggio, ASST Bergamo Ovest, Guido Arpaia, Bergamo., Giovanni Barillari, U. O. Medicina Interna Carate Brianza ASST-Vimercate., SOS di Dipartimento 'Malattie Emorragiche, e Trombotiche, Azienda Sanitaria Universitaria Friuli Centrale, Giuseppina Bitti, Presidio Ospedaliero Universitario 'Santa Maria della Misericordia'. Udine., Giuseppe Pio Martino Medicina Interna Ospedale Civile di Fermo, Eugenio Bucherini, Fermo (Ancona)., Antonio Chistolini, Monica Vastola— SS Az. le di Angiologia Faenza (RA) AUSL Romagna., Alessandra, Serrao, Dipartimento di Medicina Traslazionale, e di Precisione, Egidio De Gaudenzi, Sapienza Universita di Roma., Valeria De Micheli, SOC Medicina Interna Ospedale San Biagio – Domodossola., Anna Falanga, Ambulatorio Emostasi—Azienda Ospedaliera Di Lecco., Teresa, Lerede, Luca, Barcella, Laura, Russo, Usc, Simt, Centro Emostasi, e Trombosi, Ospedale Papa Giovanni XXIII, Vittorio Fregoni, Bergamo., Medicina Generale, U. O. C., Silvia Galliazzo, ASST Valtellina e Alto Lario Ospedale di Sondalo., UOC Medicina Generale, Ospedale San Valentino, Alberto Gandolfo, Montebelluna (TV)., Gianni, Biolo, Valentina, Trapletti, SC (UCO) Clinica Medica, Azienda sanitaria universitaria Giuliano Isontina (ASU GI)—Ospedale di Cattinara, Trieste, Ghigliotti, Giorgio, Elisa Grifoni, Clinica Delle Malattie Dell'apparato Cardiovascolare Policlinico San Martino Genova., Luca, Masotti, Medicina Interna, 2, Ospedale San Giuseppe, Egidio Imbalzano, Empoli (Fi)., UOC Medicina Interna, Gianfranco Lessiani, Policlinico di Messina., Unita, Angiologica, Dipartimento di Medicina, e Geriatria, Ospedale, Citta, Sant'Angelo, Niccolo Marchionni, Pescara., SOD Cardiologia Generale, Dipartimento, Cardiotoracovascolare, Aou, Careggi, Giuliana Martini, Firenze., Sara, Merelli, Nicola Portesi Centro Emostasi, Spedali Civili Di Brescia, Franco, Mastroianni, Giovanni, Larizza, Covid, Unit, Miulli, EE Ospedale Generale F., Carlo Nozzoli, Acquaviva delle Fonti (Ba)., SOD Medicina Interna, 1, Dipartimento di Emergenza AOU- Careggi, Serena Panarello, Firenze., Fioravanti, Chiara, SC Medicina Interna, Galliera, Eo, Simona Pedrini, Genova., Federica, Bertola, Servizio di Laboratorio, Istituto Ospedaliero Fondazione Poliambulanza, Raffaele Pesavento, Brescia., Filippo Pieralli, Davide Ceccato UO Clinica Medica 3 Azienda Ospedaliero Universitaria Padova., SOD Medicina Interna ad alta intensita, Dipartimento di Emergenza, AOU-, Careggi, Pasquale Pignatelli, Firenze., Daniele, Pastori, Centro, Trombosi, Clinica Medica, I, Paola Preti, Universita La Sapienza Roma., Centro Emostasi, e Trombosi Medicina Generale II, Matteo, IRCCS Fondazione Policlinico S., Elias Romano, Pavia., Alessandro, Morettini, Girolamo Sala, AOU-Careggi Firenze., Fabrizio, Foieni, Michela, Provisone, UOC Medicina II, Luca Sarti, Ospedale di Circolo Busto Arsizio (Va)., Antonella, Caronna, Struttura complessa di medicina interna ed area critica, Federico Simonetti, Ospedale di Baggiovara (Mo)., Ilaria, Bertaggia, Piera Sivera, UOC Ematologia Aziendale – Ospedale Versilia –Lido di Camaiore (Lucca)., Carmen, Fava, Ematologia e terapie cellulari, S. C. D. U., Viviana Scancassani, AO Ordine Mauriziano Umberto 1° Torino., Michele Spinicci, ASST Valtellina UOC di Medicina Sondrio., Alessio, Bartoloni, SOD Malattie Infettive, e Tropicali, Adriana Visona, Firenze., Beniamino, Zalunardo, Uoc, Angiologia, Ospedale San Giacomo Apostolo, Sabina Villalta, Castelfranco Veneto (Treviso)., and Castelfranco Veneto, (Treviso).
- Subjects
Heparin ,Anticoagulants ,COVID-19 ,Antithrombotic ,COVID-19 disease ,Mortality ,Hemorrhage ,Venous Thromboembolism ,Heparin, Low-Molecular-Weight ,Im - Original ,COVID-19 disease, Antithrombotic, Heparin, Mortality ,Fibrinolytic Agents ,Emergency Medicine ,Internal Medicine ,Humans ,Hospital Mortality ,Pulmonary Embolism ,Retrospective Studies - Abstract
COVID-19 infection causes respiratory pathology with severe interstitial pneumonia and extra-pulmonary complications; in particular, it may predispose to thromboembolic disease. The current guidelines recommend the use of thromboprophylaxis in patients with COVID-19, however, the optimal heparin dosage treatment is not well-established. We conducted a multicentre, Italian, retrospective, observational study on COVID-19 patients admitted to ordinary wards, to describe clinical characteristic of patients at admission, bleeding and thrombotic events occurring during hospital stay. The strategies used for thromboprophylaxis and its role on patient outcome were, also, described. 1091 patients hospitalized were included in the START-COVID-19 Register. During hospital stay, 769 (70.7%) patients were treated with antithrombotic drugs: low molecular weight heparin (the great majority enoxaparin), fondaparinux, or unfractioned heparin. These patients were more frequently affected by comorbidities, such as hypertension, atrial fibrillation, previous thromboembolism, neurological disease, and cancer with respect to patients who did not receive thromboprophylaxis. During hospital stay, 1.2% patients had a major bleeding event. All patients were treated with antithrombotic drugs; 5.4%, had venous thromboembolism [30.5% deep vein thrombosis (DVT), 66.1% pulmonary embolism (PE), and 3.4% patients had DVT + PE]. In our cohort the mortality rate was 18.3%. Heparin use was independently associated with survival in patients aged ≥ 59 years at multivariable analysis. We confirmed the high mortality rate of COVID-19 in hospitalized patients in ordinary wards. Treatment with antithrombotic drugs is significantly associated with a reduction of mortality rates especially in patients older than 59 years.
- Published
- 2022
- Full Text
- View/download PDF